Drugs for Lymph Node Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 26)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Letrozole |
Approved, Investigational |
Phase 3 |
|
112809-51-5 |
3902 |
Synonyms:
4,4'-(1H-1,2,4-Triazol-1-yl-methylene)-bis(benzonitrile)
CGS-20267
FEM345
Femara
Fémara
|
Femara®
Letrozol
LETROZOLE
Novartis brand OF letrozole
|
|
2 |
|
Capecitabine |
Approved, Investigational |
Phase 3 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
3 |
|
Tamoxifen |
Approved |
Phase 3 |
|
10540-29-1, 54965-24-1 |
2733526 |
Synonyms:
(Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine
(Z)-2-(Para-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine
1-Para-b-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-beta-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-Para-β-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
1-p-Î’-dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene
Apo-tamox
Citofen
Citrate, tamoxifen
Crisafeno
Diemon
EMBLON
FENTAMOX 10
FENTAMOX 20
Gen-tamoxifen
I.C.I.46474 CITRATE
ICI-46474
ICI-46474|Nolvadex®|Soltamox®
ICI-47699
Istubol
KENTADEX
KESSAR
KESSAR 10
KESSAR 20
Noltam
Nolvadex
NOLVADEX D
NOLVADEX FTE
Nolvadex-D
Nourytam
|
Novaldex
Novo-Tamoxifen
OESTRIFEN-10
OESTRIFEN-20
OESTRIFEN-40
Oncomox
PMS-Tamoxifen
Retaxim
Savient brand OF tamoxifen citrate
Soltamox
Tamizam
Tamofen
Tamone
Tamoplex
Tamoxasta
Tamoxen
TAMOXIFEN
Tamoxifen citrate
Tamoxifene
TAMOXIFÈNE
Tamoxifene [INN-French]
Tamoxifeno
Tamoxifeno [INN-Spanish]
Tamoxifenum
Tamoxifenum [INN-Latin]
Tomaxithen
trans-Tamoxifen
Valodex
ZD6157
Zemide
Zitazonium
ZYNOPLEX
|
|
4 |
|
Progesterone |
Approved, Vet_approved |
Phase 3 |
|
57-83-0 |
5994 |
Synonyms:
(1S,2R,10S,11S,14S,15S)-14-ACETYL-2,15-DIMETHYLTETRACYCLO[8.7.0.0^{2,7}.0^{11,15}]HEPTADEC-6-EN-5-ONE
(8S,9S,10R,13S,14S,17S)-17-ACETYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(8S,9S,10R,13S,14S,17S)-17-ETHANOYL-10,13-DIMETHYL-1,2,6,7,8,9,11,12,14,15,16,17-DODECAHYDROCYCLOPENTA[A]PHENANTHREN-3-ONE
(S)-4-PREGNENE-3,20-DIONE
(S)-PREGN-4-EN-3,20-DIONE
(S)-PROGESTERONE
17ALPHA-PROGESTERONE
17A-PROGESTERONE
17Α-PROGESTERONE
3,20-PREGNENE-4
4-PREGNEN-3,20-DIONE
4-PREGNENE-3,20-DIONE
AGOLUTIN
AKROLUTIN
Amen
BETA-PROGESTERONE
BIO-LUTON
CIDR
COLPROSTERONE
CORLUTIN
CORLUTINA
CORLUVITE
CORPORIN
CORPUS LUTEUM HORMONE
CRINONE
CRINONE PROGESTERONE GEL
CURRETAB
CYCLOGEST
CYCLOGESTERIN
Cycrin
D4-PREGNENE-3,20-DIONE
DELALUTIN
DELTA(4)-PREGNENE-3,20-DIONE
DELTA(SUP 4)-PREGNENE-3,20-DIONE
DURAPROGEN
ENDOMETRIN
ESTIMA
FLAVOLUTAN
FOLOGENON
Gelbkoerperhormon
GELBKÖRPERHORMON
GESTEROL
GESTEROL 100
GESTEROL 50
GESTIRON
GESTONE
GESTORMONE
GESTRON
GLANDUCORPIN
GYNLUTIN
GYNOLUTON
GYNOLUTONE
HORMOFLAVEINE
HORMOLUTON
Hydroxyprogesterone caproate
Hydroxyprogesterone caproic acid
LINGUSORBS
LIPO-LUTIN
LUCORTEUM
LUCORTEUM SOL
LUGESTERON
LUTEAL HORMONE
Luteinique
LUTEOCRIN NORMALE
LUTEODYN
LUTEOGAN
LUTEOHORMONE
LUTEOL
LUTEOPUR
LUTEOSAN
LUTEOSTAB
LUTEOVIS
LUTEUM
LUTEX
LUTIDON
LUTIGEST
|
Lutin
LUTOCICLINA
LUTOCUCLIN M
LUTOCYCLIN
LUTOCYCLIN M
LUTOCYLIN
LUTOCYLOL
LUTOFORM
LUTOGYL
LUTOGYNON
LUTREN
LUTROMONE
MEMBRETTES
METHYLPREGNONE
MPA
NALUTRON
NSC-64377
NSC-9704
PERCUTACRINE
PERCUTACRINE LUTEINIQUE
PIAPONON
PRANONE
PREGN-4-EN-3,20-DIONE
PREGN-4-ENE-3,20-DIONE
PREGNENE-3,20-DIONE
PREGNENEDIONE
PRIMOLUT
PROCHIEVE
PROGEFFIK
PROGEKAN
PROGESTA-CARE
PROGESTAN
PROGESTASERT
PROGESTEROL
PROGESTERON
PROGESTERONA
Progesterona [INN-Spanish]
PROGESTERONE
PROGESTÉRONE
Progesterone, (13 alpha,17 alpha)-(+-)-isomer
Progesterone, (17 alpha)-isomer
Progesterone, (9 beta,10 alpha)-isomer
PROGESTERONUM
Progesteronum [INN-Latin]
PROGESTIN
PROGESTOGEL
PROGESTOL
PROGESTON
PROGESTONE
PROGESTOSOL
PROGESTRON
PROGESTRONOL
PROJESTAJECT
PROLETS
PROLIDON
PROLUTIN
PROLUTON
PROLUTONE
PROMETRIUM
Prometrium®|Utrogestan®
PRONTOGEST
PROTORMONE
REGUMATE
SERENITY FOR WOMEN
SYNGESTERONE
SYNGESTRETS
SYNGESTRONE
SYNOVEX S
SYNTOLUTAN
Thiuram E
Thiuranide
U 3672
UTROGEST
UTROGESTAN
VITARRINE
Δ(4)-pregnene-3,20-dione
|
|
5 |
|
Docetaxel |
Approved, Investigational |
Phase 3 |
|
114977-28-5 |
148124 |
Synonyms:
CKD-810
Docecad®|docetaxel anhydrous|EmDOC|Taxotere®
DOCEFREZ
DOCETAXEL
Docetaxel anhydrous
Docetaxel hydrate
Docetaxel trihydrate
Docetaxel, trihydrate
Docetaxol
N Debenzoyl N tert butoxycarbonyl 10 deacetyltaxol
|
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-Debenzoyl-N-tert-butoxycarbonyl-10-deacetyltaxol
NSC-628503
RP-56976
TAXCEUS
Taxoltere metro
Taxotere
TXL
XRP6976
|
|
6 |
|
Antineoplastic Agents, Hormonal |
|
Phase 3 |
|
|
|
7 |
|
Estrogens |
|
Phase 3 |
|
|
|
8 |
|
Estrogen Receptor Modulators |
|
Phase 3 |
|
|
|
9 |
|
Estrogen Receptor Antagonists |
|
Phase 3 |
|
|
|
10 |
|
Estrogen Antagonists |
|
Phase 3 |
|
|
|
11 |
|
Hormones |
|
Phase 3 |
|
|
|
12 |
|
Antimitotic Agents |
|
Phase 3 |
|
|
|
13 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
14 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
15 |
|
Tubulin Modulators |
|
Phase 3 |
|
|
|
16 |
|
Aromatase Inhibitors |
|
Phase 3 |
|
|
|
17 |
|
Selective Estrogen Receptor Modulators |
|
Phase 3 |
|
|
|
18 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
19 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
20 |
|
Immunoglobulins |
|
Phase 2 |
|
|
|
21 |
|
Immune Checkpoint Inhibitors |
|
Phase 2 |
|
|
|
22 |
|
Antibodies |
|
Phase 2 |
|
|
|
23 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
24 |
|
Pancrelipase |
Approved, Investigational |
|
|
53608-75-6 |
8519 |
Synonyms:
1,4-ALPHA-D- GLUCAN GLUCANOHYDROLASE
ACCELERASE
COTAZYM
COTAZYM-S
CREON
Endothall
Endothall dipotassium salt
Endothall disodium salt
Endothall disodium salt, (endo,endo)-isomer
Endothall, diammonium salt
ENTOLASE
ILOZYME
KU-ZYME HP
LIPANCREATIN
lipase
|
PA
Pancrealipase
PANCREASE
PANCREATIC ALPHA-AMYLASE PRECURSOR
Pancreatic extract pancrelipase
Pancreatic protease
Pancreatin
Pancreatinum
PANCRELIPASE
Pancrelipase (amylase
PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)
protease)
VIOKASE
ZYMASE
|
|
25 |
|
Imidacloprid |
Vet_approved |
|
|
105827-78-9 |
86418 |
Synonyms:
(2E)-1-[(6-chloropyridin-3-yl)methyl]-N-nitroimidazolidin-2-imine
(e)-Imidacloprid
(Z)-Imidacloprid
1-((6-Chloro-3-pyridinyl)methyl)-N-nitro-2-imidazolidinimine
1-((6-Chloro-3-pyridyl)methyl)-N-nitro-2-imidazolidinimine
1-(2-chloro-5-Pyridylmethyl)-2-(nitroimino)imidazolidine
1-[(6-chloro-3-Pyridinyl)methyl]-4,5-dihydro-N-nitro-1H-imidazol-2-amine, 9ci
Admire
Advantage
Advantage flea adulticide
Bayer brand OF imidacloprid
|
Confidor
Confidor 200 SL
Confidor SL
Gaucho
IMD
IMIDACLOPRID
Imidacloprid (old RN)
Merit
Merit (insecticide)
Premise 75
Provado
|
|
26 |
|
Pancreatin |
|
|
|
|
|
Interventional clinical trials:
(show all 16)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Randomised Clinical Trial of Surgery Versus Surgery Plus Adjuvant Radiotherapy for Regional Control in Patients With Completely Resected Macroscopic Nodal Metastatic Melanoma |
Completed |
NCT00287196 |
Phase 3 |
|
2 |
MINDACT (Microarray In Node-Negative and 1 to 3 Positive Lymph Node Disease May Avoid Chemotherapy): A Prospective, Randomized Study Comparing the 70-Gene Signature With the Common Clinical-Pathological Criteria in Selecting Patients for Adjuvant Chemotherapy in Breast Cancer With 0 to 3 Positive Nodes |
Completed |
NCT00433589 |
Phase 3 |
anthracycline-based;docetaxel and capecitabine;tamoxifen;Letrozole |
3 |
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy |
Active, not recruiting |
NCT01901094 |
Phase 3 |
|
4 |
Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease |
Active, not recruiting |
NCT03618641 |
Phase 2 |
CMP-001 |
5 |
Investigating the Feasibility of Fluorescence Targeted Pelvic Lymph Node Mapping During Rectal Cancer Surgery |
Terminated |
NCT03204994 |
Phase 1, Phase 2 |
Indocyanine Green |
6 |
Role of Color Doppler Ultrasound in Differentiation Between Benign and Malignant Lymphadenopathy |
Unknown status |
NCT03760094 |
|
|
7 |
Prediction Model Based on Deep Learning of CP-EBUS Multimodal Image in the Diagnosis of Benign and Malignant Lymph Nodes |
Unknown status |
NCT04328792 |
|
|
8 |
Prospective Analysis of the Survival of Patients With a Reduction in the Number of Lymph Nodes in Rectal Cancer After Neoadjuvant Chemoradiotherapy |
Unknown status |
NCT04456283 |
|
|
9 |
Prospective Evaluation of the Diagnostic Efficacy of a EUS Guided FNB Needle (AQUIRE®) in Tumors of the Pancreas, Submucosal Tumors and Lymph Node Disease of the Upper GI Tract |
Unknown status |
NCT03621852 |
|
|
10 |
Retrospektive Analyse Der Radiotherapie Des Pelvinen Lymphabflusses Beim Lokalisierten Prostatakarzinom Vom Hochrisikotyp Anhand Der Klinikdatenbank 2010-2016 |
Completed |
NCT02998619 |
|
|
11 |
Diagnostic Value of Radiographic Characteristics of Mediastinal and Hilar Lymph Nodes in Sarcoidosis |
Completed |
NCT04735302 |
|
|
12 |
Evolution of Indications for Transbronchial Ganglionic Ultrasound in the Picardie Region Over the Period 2008 - 2013 |
Completed |
NCT03132883 |
|
|
13 |
Identifying Ultrasonic Diagnostic Characteristics of Cervical Lymphadenopathy: A Retrospective, Multicenter Study |
Completed |
NCT04497714 |
|
|
14 |
Comparion of 22G-ProCore and 22G-Standard Needle in Diagnosis of Lymphadenopathy Via EBUS-TBNA: A Prospective, Single-center, Randomized Controlled Clinical Trial |
Recruiting |
NCT03903471 |
|
|
15 |
The Role of Micrometastasis and Isolated Tumor Cells (ITCs) in Uterine Cancers (Endometrial/Cervical) Submitted to Sentinel Lymph Nodes (SLN) Procedure: an Observational Study |
Recruiting |
NCT04403867 |
|
|
16 |
Performing a Lymphatic-venous Anastomosis at Time of Nodal Dissection in Patients Requiring Complete Axillary or Groin Dissection for the Prevention of Lymphedema |
Terminated |
NCT03073096 |
|
|
|